Phase I Study of P276-00 in Patients With Advanced Refractory Neoplasms

NCT00408018 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
28
Enrollment
INDUSTRY
Sponsor class

Stopped The decision to terminate this study after 202 mg/m2 cohort was taken as MTD achieved in other study at 185 mg/m2

Conditions

Interventions

Sponsor

Piramal Enterprises Limited